- Home
- BBAI vs EWTX Comparison
BBAI vs EWTX Comparison
Compare BBAI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- EWTX
- Stock Information
- Founded
- BBAI 2020
- EWTX 2017
- Country
- BBAI United States
- EWTX United States
- Employees
- BBAI N/A
- EWTX N/A
- Industry
- BBAI EDP Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- EWTX Health Care
- Exchange
- BBAI Nasdaq
- EWTX Nasdaq
- Market Cap
- BBAI 1.0B
- EWTX 1.2B
- IPO Year
- BBAI N/A
- EWTX 2021
- Fundamental
- Price
- BBAI $3.25
- EWTX $14.70
- Analyst Decision
- BBAI Strong Buy
- EWTX Buy
- Analyst Count
- BBAI 3
- EWTX 8
- Target Price
- BBAI $5.17
- EWTX $40.13
- AVG Volume (30 Days)
- BBAI 56.5M
- EWTX 1.2M
- Earning Date
- BBAI 05-01-2025
- EWTX 05-08-2025
- Dividend Yield
- BBAI N/A
- EWTX N/A
- EPS Growth
- BBAI N/A
- EWTX N/A
- EPS
- BBAI N/A
- EWTX N/A
- Revenue
- BBAI $159,872,000.00
- EWTX N/A
- Revenue This Year
- BBAI $9.65
- EWTX N/A
- Revenue Next Year
- BBAI $12.82
- EWTX N/A
- P/E Ratio
- BBAI N/A
- EWTX N/A
- Revenue Growth
- BBAI 9.40
- EWTX N/A
- 52 Week Low
- BBAI $1.17
- EWTX $10.60
- 52 Week High
- BBAI $10.36
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BBAI 51.52
- EWTX 42.22
- Support Level
- BBAI $2.96
- EWTX $14.08
- Resistance Level
- BBAI $3.58
- EWTX $17.30
- Average True Range (ATR)
- BBAI 0.26
- EWTX 1.00
- MACD
- BBAI 0.06
- EWTX 0.39
- Stochastic Oscillator
- BBAI 62.24
- EWTX 37.50
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.